The report includes state-specific measures of lung cancer incidence, adult smoking prevalence, estimated percent of radon tests at or above the U.S. EPA action level, five-year survival, early diagnosis, surgery as part of the first course of treatment, lack of treatment, and screening among those at high risk.
Lung cancer incidence, staging, surgical treatment, and lack of treatment data is for years 2015-2019 and includes malignant lung and bronchus tumors. These data are based on the North American Association of Central Cancer Registries (NAACCR) December 2021 data submission. In the U.S., registries also participate in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program or the Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries (NPCR) or both. Support for cancer registries is provided by the state, province or territory in which the registry is located.
Incidence data for Kansas 2014-2018 and Nevada 2013-2017 are from CDC’s WONDER Online Database United States Cancer Statistics as data from these states were not included in the NAACCR data submission.
Trend data reflect the percent change between the most recent year of data and those five years earlier if the change was statistically significant at the .05 level. If the change was not statistically significant, the trend was labeled as “flat.”
Cases diagnosed at an early stage correspond with local stage from SEER summary staging and are equivalent to stage I. Cases diagnosed at a late stage correspond with distant stage from SEER summary staging and are equivalent to stage IV.
State survival rates are the age-standardized percent of cases still alive five years after diagnosis for cases diagnosed in years 2012-2018. These data are from Cancer in North America: 2015-2019 Volume Four: Cancer Survival in the United States and Canada 2012-2018 from NAACCR. Survival data was not available for five states.
Lack of treatment is the percent of lung cancer diagnoses that did not receive any medical treatment generally associated with lung or other cancers, including the following: removal, biopsy or aspiration of regional lymph node; surgical removal of distant lymph nodes or other tissue(s)/organ(s) beyond the primary site; surgery for lung cancer; radiation; chemotherapy; systemic hormonal agents; immunotherapy; other, including experimental, double-blind, and unproven; and transplant or endocrine surgery or radiation. Rates from this year should not be compared to those from previous reports as a new variable was utilized.
Screening rates were determined by dividing the number of screening exams meeting United States Preventative Task Force (USPSTF) criteria by the estimated number of people at high risk for lung cancer and recommended for annual screening with low dose computed tomography.
Data on the number of screening exams meeting USPSTF criteria came from the American College of Radiology’s (ACR) Lung Cancer Screening Registry State Level Comparison for 2021. We believe this registry represents most lung cancer screenings as it is the only approved registry at this time, and screening facilities were required to submit data on all lung cancer screenings to it in order to meet Medicare eligibility requirements. Screening rates may be higher in states with large, regional managed care providers that did not share screening data.
This research was supported by the ACR’s National Radiology Data Registry (NRDR). The views expressed in this report represent those of the authors, and do not necessarily represent the official views of the NRDR or the ACR. The authors wish to thank the Lung Cancer Screening Registry steering committee and ACR staff for the use of registry data.
The number of people at high risk for lung cancer was based on USPSTF criteria from after March 2021, which defined high risk as ages 50-80 years of age; 20 or more pack-year history of smoking (one pack a day for 20 years, two packs a day for 10 years, etc.); and are a current smoker, or have quit within the last 15 years.
Screening rates in this report reflect a transitionary period as they are from 2021 and include those screened both before and after the guidelines were expanded, while based on the number eligible for screening under the expanded guidelines. It is not currently possible to determine what portion of those screened were newly eligible based on the expanded guidelines.
As the number of people at high risk was not available at the state level, we developed a model to adjust state estimates of current and former smokers ages 55-80 using predictors of pack year history and number of years since quitting from CDC’s 2015 National Health Interview Survey (NHIS).
The number of current and former smokers ages 55-80 for each state was estimated using 2020 Behavioral Risk Factor Surveillance System (BRFSS) data from the CDC. The 2015 NHIS was the most recent survey to include questions necessary for determining pack year history and years since quitting. Logistic regression was used to determine which variables common to both the NHIS and BRFSS best predicted a 30 or more pack-year history for current and former smokers and less than 15 years since quitting for former smokers, all aged 55-80. Reported health status (excellent, very good, good, fair, bad) by smoking status (current or former) was found to be the strongest and most parsimonious model and produced results for number at high risk and percent at high risk receiving screening similar to those from published literature. These results were the denominator for determining screening among those at high risk, with the number of screening exams meeting USPSTF criteria as the numerator.
Smoking rates are the percent of adults who have ever smoked 100 or more cigarettes and currently smoke on some days or all days using data from the 2020 BRFSS.
To assess current coverage of lung cancer screening in state Medicaid fee-for-service programs, the Lung Association surveyed state Medicaid programs to obtain information on coverage of low dose CT scans for individuals at high risk for lung cancer and reviewed publicly available coverage policies.
Radon estimates for each state are primarily based on the most recent ten-year period’s proportion of county-level pre-mitigation radon tests from occupied interior spaces at or above the U.S. Environmental Protection Agency action level of 4 pCi/L (picoCuries per liter of air) from CDC’s National Environmental Public Health Tracking for 2008-2017, limited to counties with at least ten results, weighting those fractions by U.S. Census Bureau 2019 estimates of county populations.
Hawaii radon estimates are based on “EPA's Map of Radon Zones: HAWAII” US EPA 402-R-93-031 Sept 1993 page IV-22. Kansas radon test results are from 2016, 2017, and 2019 as these were the only available years. Mississippi radon estimates are based on all Mississippi counties with summaries of results available at www.radon.com/maps.
Whole numbers are the result of rounding and are not an indication of significant digits.
States were ranked from best to worst for each cancer-specific measure. In addition, statements describing the distance from the mean for each specific state measure were crafted to provide a clearer understanding of how each specific data point falls within the national data range, and how the state data differs from the national average.
Statements such as “above average tier” and “average tier,” were determined by dividing each measure (incidence, smoking, survival, early diagnosis, surgery, lack of treatment, and screening) into two sets of five contiguous ranges; one set ranging from the maximum observed value to the national average, and the other from the national average to the minimum observed value. Data values were described by which category they fell into:
- The two lowest categories were classified as “bottom tier;”
- data values that fell into the third and fourth lowest categories were classified as “below average tier;”
- data values that fell into the two middle categories were classified as “average tier;”
- data values that fell into the third and fourth highest categories were classified as “above average tier;” and
- data values that fell into the two highest categories were classified as “top tier”
Email President Biden to thank him for his leadership on the Cancer Moonshot Initiative and urge him to work to increase lung cancer screening for individuals at high risk.
Page last updated: November 17, 2022